Two multiple-year studies into the effectiveness and safety of CooperVision’s MiSight 1 day soft contact lenses were highlighted at the recent 4th Asia-Pacific Myopia Management Symposium (APMMS) in Seoul, South Korea.
The event, in partnership with the Korean Association of Paediatric Ophthalmology and Strabismus (KAPOS), drew over 2,200 participants, both in-person and virtually, from around the globe.
Themed ‘Myopia Reframed: Shaping the Future of Eye Health’, the symposium highlightsed advancements in paediatric myopia management and featured plenary presentations and interactive panel discussions led by a diverse lineup of global experts.
CooperVision shared the findings from its seven-year clinical study on MiSight 1 day soft contact lenses for vision correction and control of the progression of myopia, the first U.S. FDA-approved soft contact lens to slow the progression of myopia in children.
In a release following the event, the company said: “Only MiSight 1 day is proven to retain myopia control benefits after treatment has ended. Other modalities, such as atropine, have been shown to produce a rebound effect.
It said the clinical study showed MiSight 1 day contact lenses were child friendly and easy to use, with 9 out of 10 children preferring MiSight 1 day over their glasses.
Additionally, a 10-year investigator-initiated study, led by Professor Nicola Logan from Aston University, UK, highlighted the safety of long-term daily disposable hydrogel soft contact lens wear, MiSight 1 day.
“After 10 years of full-time wear, children in the MiSight 1 day clinical study had clinically equivalent corneal endothelial function to non-contact lens wearers,” Prof Logan said.
Mr Shila Gupta, Myopia Management general manager at CooperVision Asia-Pacific, reflected on the symposium’s impact: “APMMS 2024 has been a pivotal event in advancing myopia management across the APAC region.
“By highlighting advancements, including our seven-year clinical study and ten-year investigator-initiated study on MiSight 1 day, we are reaffirming our commitment to setting new benchmarks in eyecare,” he said.
“We are honored to host APMMS for the 4th consecutive year and to partner with KAPOS, furthering our commitment to driving progress in myopia management and fostering collaboration within the eye care community.”
Dr. Paik Hae-Jung, president of KAPOS and Korean Myopia Society, Gachon University Gil Medical Center, Korea, said: “The 4th APMMS has been a landmark moment in shaping the future of myopia management in Korea.
“By facilitating an invaluable exchange of knowledge between Korean and global experts, we are setting new standards in myopia care and paving the way for a brighter future in children’s eye health.
“I am also pleased to announce that KAPOS has established a new arm, the Korea Myopia Society (KMS), specifically focused on myopia management. KMS aims to enhance myopia awareness, advance clinical understanding, and support eye care professionals in managing myopia more effectively.”
More reading
Optometrists get a little help from a big friend in CooperVision
Manufacturing plant wins multiple sustainability awards
CooperVision develops 24/7 training resource
